Taxus Liberte: Additional data

Additional data from the ATLAS Small Vessel study showed that Taxus Liberte significantly reduced the rates of target lesion revascularization (TLR) at 4 years vs. Taxus Express (10.8% vs. 23.8%, p=0.008). Taxus Liberte also significantly reduced the rates of target vessel revascularization (TVR) (16.5% vs.31.7%, p=0.007), target lesion failure (TL) (15.4% vs. 30.2%, p=0.007), and major adverse cardiac events (21.6% vs. 36.5%, p=0.02) at 4 years vs. Taxus Express. Data were presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington. ...